Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 10/20 | 0.60 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4897402 | 0.89 | HDAC1 (0.59) | HDAC1TRPV1KCNH2NTRK1MEN1 | |
| SCHEMBL3612433 | 0.88 | HDAC1 (0.58) | HDAC1KCNH2MEN1KMT2ANPC1 | |
| SCHEMBL8264607 | 0.86 | HDAC1 (0.53) | HDAC1TRPV1KCNH2 | |
| SCHEMBL13462579 | 0.85 | HDAC1 (0.52) | HDAC1TRPV1KCNH2NTRK1 | |
| SCHEMBL5797598 | 0.85 | HDAC1 (0.60) | HDAC1TRPV1KCNH2NTRK1MEN1 | |
| SCHEMBL3603039 | 0.84 | HDAC1 (0.84) | HDAC1KCNH2 | |
| SCHEMBL3618560 | 0.82 | HDAC1 (0.85) | HDAC1KCNH2 | |
| SCHEMBL3611034 | 0.81 | HDAC1 (0.85) | HDAC1KCNH2 | |
| SCHEMBL3612988 | 0.78 | HDAC1 (0.74) | HDAC1KCNH2 | |
| SCHEMBL14182609 | 0.76 | HDAC1 (0.53) | HDAC1TRPV1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2215075-B1 | QUINOLINONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-11 | — | — | EP | disclosed |
| US-8404713-B2 | Quinolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-26 | — | — | US | disclosed |
| US-20100222348-A1 | QUINOLINONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-02 | — | — | US | disclosed |
| US-20100075942-A1 | N-PHENYL-4-PYRIDIN-2-YL-BENZAMIDE DERIVATIVES AS HISTONE DEACYLASE (HDAC) INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB | 2010-03-25 | — | — | US | disclosed |
| WO-2006075160-A1 | N-PHENYL-4-PYRIDIN-2-YL-BENZAMIDE DERIVATIVES AS HISTONE DEACYLASE (HDAC) INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075942-A1 | N-PHENYL-4-PYRIDIN-2-YL-BENZAMIDE DERIVATIVES AS HISTONE DEACYLASE (HDAC) INHIBITORS FOR THE TREATMENT OF CANCER | HDAC1, HDAC2, HDAC3 | HDAC1 1/4885TRPV1 2925/4885KCNH2 2678/4885 |
| US-20100222348-A1 | QUINOLINONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP11 | HDAC1 95/4885TRPV1 4410/4885KCNH2 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.